This requires Flash to play. Click here to download.

The information on this site is intended for health care professionals
in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety profile Dosage Reimbursement Resource center CTCL overview Prescribing Information Patient Information
Patient Product Information

Incidence and prevalence

  • The incidence of CTCL in the United States is approximately 1,500 new cases per year.1
  • The prevalence of CTCL in the United States ranges from 16,000 to 20,000 cases.2
  • In general, patients with T1 disease (the earliest skin lesions, such as patches covering <10% of the body surface area), have the longest survival. These patients survive longer than those with T2 disease with the same type of skin lesions covering ≥10% of the body surface area.
  • The prognosis for patients with skin tumors (T3 disease) is significantly worse than for patients with T1 or T2 disease. Survival is better for patients with skin tumors involving <10% of the body surface area than for those with ≥10% involved with tumors. As the skin lesions progress, the likelihood that the patient will develop lymph node involvement increases, and the chance for long-term survival worsens.1,2
TNM Classification for CTCLs
Stage at Diagnosis3 Patients at Diagnosis, %3
T1: Patches/plaques covering <10% of body surface 42
T2: Patches/plaques covering ≥10% of body surface 30
T3: Tumor(s) 15
T4: Erythroderma 12
References: 1. The Lymphoma & Leukemia Society. Cutaneous T cell lymphoma. http://leukemia-lymphoma.org/attachments/National/br_1163608564.pdf. Published November 2006. Accessed November 3, 2008. 2. Cutaneous Lymphoma Foundation. CTCL-MF fast facts. http://clfoundation.org/publications/CL_fast_facts.pdf. Accessed November 3, 2008. 3. Habermann TM, Pittelkow MR. Cutaneous T-cell lymphoma and cutaneous B-cell lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Clinical Oncology. 3rd ed. New York, NY: Churchill Livingstone; 2004:3077–3108.

Home | Patient Information | Prescribing Information
ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

20951007(3)-05/09-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.